Truist Financial’s Verona Pharma VRNA Stock Holding History

Truist Financial’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,388	Closed	-$575K	–	2866
2025 Q3	$575K	Sell	5,388 -3,221	-37%	-$336K	﹤0.01%	1948
2025 Q2	$814K	Sell	8,609 -184	-2%	-$13.6K	﹤0.01%	1703
2025 Q1	$558K	Sell	8,793 -167	-2%	-$9.99K	﹤0.01%	1806
2024 Q4	$416K	Buy	8,960 +92	+1%	+$3.45K	﹤0.01%	1982
2024 Q3	$255K	Buy	+8,868	New	+$218K	﹤0.01%	2234
2023 Q1	–	Sell	-11,600	Closed	-$303K	–	2678
2022 Q4	$303K	Buy	+11,600	New	+$154K	﹤0.01%	2230

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Truist Financial's VRNA Position: Q4 2025 in Review

Truist Financial sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 5,388 shares — an estimated $575K sold.

Truist Financial first reported a position in VRNA in Q4 2022 and held it in 6 quarters. The position peaked at $814K in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Truist Financial reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Truist Financial sold 5,388 Verona Pharma shares in Q4 2025, an estimated $575K.
Truist Financial first reported a position in Verona Pharma in Q4 2022 and held it in 6 quarters.
Truist Financial's Verona Pharma position peaked at $814K in Q2 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Truist Financial's 13F filing for Q4 2025, filed 2 Feb 2026.